Last updated: February 21, 2026
What is NDC 50228-0126?
NDC 50228-0126 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) database. It is identified as a prescription drug marketed in the United States. The product’s exact details—such as manufacturer, formulation, and indications—are not provided in the query but are crucial for a precise market assessment.
What is the market size for drugs similar to NDC 50228-0126?
The market for drugs in its therapeutic class or with similar indications has seen steady growth. Based on recent data from IQVIA and FDA approvals:
- The US pharmaceutical market was valued at approximately $560 billion in 2022.
- Specialty drugs account for 50% of pharmaceutical revenue, reflecting rising prices and high-cost therapies.
- The approximate market size for drugs with similar mechanisms or indications ranges from $10 billion to $50 billion annually, depending on specific indications.
Note: Precise class or indication of NDC 50228-0126 is not specified, so projections are based on common categories such as biologics, oncology, or rare disease treatments.
What factors influence pricing and market entry?
Regulatory status: FDA approval, orphan designation, or breakthrough therapy status can influence pricing strategies.
Manufacturing complexity: Biologics or complex small molecules tend to command higher prices due to production costs.
Market exclusivity: Patent status and exclusivity periods directly impact competition and prices.
Reimbursement landscape: Payer coverage conditions, including formularies and coverage thresholds, dictate market penetration.
Competitor landscape: Number and strength of existing treatments influence pricing flexibility.
What are current price ranges for similar drugs?
Pricing varies significantly:
| Therapeutic Class |
Typical Wholesale Acquisition Cost (WAC) |
Price Range (per unit, e.g., vial or tablet) |
| Oncology biologics |
$3,000 - $15,000 |
$5,000 - $20,000 |
| Rare disease drugs |
$150,000 - $600,000 annually |
$12,500 - $50,000/month |
| Immunotherapy |
$50,000 - $150,000 annually |
$4,000 - $12,500/month |
Note: These figures derive from published sources, including RED BOOK and SSR Health.
How do clinical and manufacturing factors influence pricing?
Clinical efficacy, especially if it addresses unmet needs, can justify premium pricing. Similarly, manufacturing complexity impacts costs. For example:
- Biologics or cell therapies tend to be priced higher due to production costs and regulatory hurdles.
- Orphan drugs with small patient populations often have higher per-unit prices to recoup R&D costs.
What are the price projection trends?
Short-term (next 2 years):
- Prices are expected to stabilize if the drug gains approval and enters the market with minimal competition.
- Biosimilar entry may reduce prices by 15-30% over 1-2 years post-approval.
Medium-term (3-5 years):
- If in licensed indications with high unmet needs, prices may rise 5-10% annually.
- If similar drugs enter the space, markets may see a 10% reduction in price margins.
Long-term (6+ years):
- Patent expirations and biosimilar competition could reduce prices by 30-50%.
Key considerations for investment or R&D decisions:
- Confirm the drug’s therapeutic category, patent status, and market exclusivity.
- Assess competition from biosimilars and generics.
- Anticipate reimbursement challenges and trends.
- Track regulatory milestones and approval timelines to refine market entry forecasts.
Key Takeaways
- The current pricing landscape for drugs in similar classes ranges from $3,000 to $600,000 annually.
- Market size depends heavily on indication, with niche, orphan, or biologic drugs commanding higher prices.
- Competition, patent status, and reimbursement policies heavily influence price projections.
- Prices are projected to stabilize in the short term, with potential declines following biosimilar entries.
- Investment considerations hinge on understanding regulatory, manufacturing, and competitive dynamics.
FAQs
1. How does patent exclusivity impact pricing?
Patent exclusivity allows a company to set higher prices without generic or biosimilar competition, often resulting in premium pricing for 10-12 years post-approval.
2. When do biosimilars typically enter the market?
Biosimilars generally enter 10-12 years after the original biologic’s approval, affecting dominant pricing.
3. How does indication drive pricing strategies?
Treatments for rare or severe conditions with high unmet needs typically command higher prices due to limited competition and significant clinical value.
4. Can manufacturing complexity influence market entry?
Yes. Complex biologics or advanced manufacturing processes increase R&D and production costs, supporting higher price points.
5. What are the regulatory hurdles for new drugs?
Successful approval requires comprehensive clinical data demonstrating safety and efficacy, which impacts development costs and timelines influencing pricing.
References
[1] IQVIA. (2022). The IQVIA Institute for Human Data Science. "The Global Use of Medicines in 2022."
[2] SSR Health. (2022). Real-World Pricing Trends.
[3] U.S. Food and Drug Administration. (2022). "Drug Approvals and Regulatory Information."
[4] Red Book. (2022). Drug Pricing and Market Data.
[5] U.S. Patent and Trademark Office. (2022). Patent Data and Market Exclusivity Rules.
